Radiotherapy in the management of synchronous metastatic lung cancer
Cancer Radiother. 2023 Aug 11:S1278-3218(23)00135-X. doi: 10.1016/j.canrad.2023.03.002. Online ahead of print.ABSTRACTMetastatic lung cancer classically portends a poor prognosis. The management of metastatic lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors, targeted therapy and due to a better understanding of the oligometastatic process. In metastatic lung cancers, radiation therapy which was only used with palliative intent for decades, represents today a promising way to treat primary and oligometastatic sites with a curative intent. Herein we present through a literature review t...
Source: Cancer Radiotherapie - August 13, 2023 Category: Cancer & Oncology Authors: J Khalifa A L évy L-M Sauvage S Thureau J Darr éon C Le P échoux D Lerouge N Pourel D Antoni E Blais É Martin A Marguerit P Giraud F-G Riet Source Type: research
Radiotherapy in the management of synchronous metastatic lung cancer
Cancer Radiother. 2023 Aug 11:S1278-3218(23)00135-X. doi: 10.1016/j.canrad.2023.03.002. Online ahead of print.ABSTRACTMetastatic lung cancer classically portends a poor prognosis. The management of metastatic lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors, targeted therapy and due to a better understanding of the oligometastatic process. In metastatic lung cancers, radiation therapy which was only used with palliative intent for decades, represents today a promising way to treat primary and oligometastatic sites with a curative intent. Herein we present through a literature review t...
Source: Cancer Radiotherapie - August 13, 2023 Category: Cancer & Oncology Authors: J Khalifa A L évy L-M Sauvage S Thureau J Darr éon C Le P échoux D Lerouge N Pourel D Antoni E Blais É Martin A Marguerit P Giraud F-G Riet Source Type: research
Radiotherapy in the management of synchronous metastatic lung cancer
Cancer Radiother. 2023 Aug 11:S1278-3218(23)00135-X. doi: 10.1016/j.canrad.2023.03.002. Online ahead of print.ABSTRACTMetastatic lung cancer classically portends a poor prognosis. The management of metastatic lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors, targeted therapy and due to a better understanding of the oligometastatic process. In metastatic lung cancers, radiation therapy which was only used with palliative intent for decades, represents today a promising way to treat primary and oligometastatic sites with a curative intent. Herein we present through a literature review t...
Source: Cancer Radiotherapie - August 13, 2023 Category: Cancer & Oncology Authors: J Khalifa A L évy L-M Sauvage S Thureau J Darr éon C Le P échoux D Lerouge N Pourel D Antoni E Blais É Martin A Marguerit P Giraud F-G Riet Source Type: research
Radiotherapy in the management of synchronous metastatic lung cancer
Cancer Radiother. 2023 Aug 11:S1278-3218(23)00135-X. doi: 10.1016/j.canrad.2023.03.002. Online ahead of print.ABSTRACTMetastatic lung cancer classically portends a poor prognosis. The management of metastatic lung cancer has dramatically changed with the emergence of immune checkpoint inhibitors, targeted therapy and due to a better understanding of the oligometastatic process. In metastatic lung cancers, radiation therapy which was only used with palliative intent for decades, represents today a promising way to treat primary and oligometastatic sites with a curative intent. Herein we present through a literature review t...
Source: Cancer Radiotherapie - August 13, 2023 Category: Cancer & Oncology Authors: J Khalifa A L évy L-M Sauvage S Thureau J Darr éon C Le P échoux D Lerouge N Pourel D Antoni E Blais É Martin A Marguerit P Giraud F-G Riet Source Type: research
Impact of immunotherapy on the therapeutic strategy for the management of stage I non-small cell lung cancer: The radiation oncologist's point of view
Cancer Radiother. 2023 Aug 10:S1278-3218(23)00142-7. doi: 10.1016/j.canrad.2023.06.028. Online ahead of print.ABSTRACTSurgery is the standard treatment for operable patients with stage I non-small cell lung cancer (NSCLC) (T1-T2aN0M0). Stereotactic body radiotherapy (SBRT) is the treatment of choice for non-operable patients, and its positioning for operable patients remains to be clarified. The pattern of recurrence after management of stage I NSCLC is dominated by the risk of distant recurrence, this constituting the rationale for the adjunction of systemic treatment, and especially check point inhibitor (CPI), in combin...
Source: Cancer Radiotherapie - August 12, 2023 Category: Cancer & Oncology Authors: J Khalifa Source Type: research
Clinical research in general hospital centres in France, strengths and weaknesses
Cancer Radiother. 2023 Aug 10:S1278-3218(23)00150-6. doi: 10.1016/j.canrad.2023.07.008. Online ahead of print.ABSTRACTClinical research is an essential activity in cancer care. Both for patients, who can gain access to innovative therapies, and for practitioners, who can maintain their skills and stay at the forefront of new treatment approaches. First developed in university hospitals, clinical research is now established in general hospitals and private health institutions. The number of patient inclusions in clinical trials has doubled over the last ten years, thus reflecting the dynamism of it. Strengths and weaknesses...
Source: Cancer Radiotherapie - August 12, 2023 Category: Cancer & Oncology Authors: D Argo-Leignel P Bouju M Le Saux N Leissen R Gu égan Y Pointreau Y Alexandre G Bera Source Type: research
Ethical stakes of information in radiation oncology: Thinking the risk and building the therapeutic alliance
Cancer Radiother. 2023 Aug 10:S1278-3218(23)00119-1. doi: 10.1016/j.canrad.2023.06.006. Online ahead of print.ABSTRACTInforming patients before receiving radiation therapy is a fundamental ethical imperative. As a condition of the possibility of autonomy, information allows people to make health decisions concerning themselves, which is required by French law. This information includes in particular the potential risks due to radiation therapy. It is therefore necessary to think about what risk is, and how to define and assess it, in order to finally communicate it. The practice of informing people involves many ethical is...
Source: Cancer Radiotherapie - August 12, 2023 Category: Cancer & Oncology Authors: T Haaser L Lahmi D Osman C Gesbert V Cheval Y Constantinides R de Crevoisier C Dejean A Escande Y Ghannam F Lorchel S Thureau J L Lagrange C Durdux F Huguet Commission éthique de la SFRO Source Type: research
Stereotactic radiotherapy for operable stage I non-small cell lung cancer
This article reviews the available data in the literature of the place of stereotactic body radiotherapy for medically operable patients with stage I non-small cell lung cancer.PMID:37563012 | DOI:10.1016/j.canrad.2023.07.012 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - August 10, 2023 Category: Cancer & Oncology Authors: É Martin C Nicolet P Boisselier J Khalifa S Thureau Source Type: research
Stereotactic radiotherapy for operable stage I non-small cell lung cancer
This article reviews the available data in the literature of the place of stereotactic body radiotherapy for medically operable patients with stage I non-small cell lung cancer.PMID:37563012 | DOI:10.1016/j.canrad.2023.07.012 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - August 10, 2023 Category: Cancer & Oncology Authors: É Martin C Nicolet P Boisselier J Khalifa S Thureau Source Type: research
Stereotactic radiotherapy for operable stage I non-small cell lung cancer
This article reviews the available data in the literature of the place of stereotactic body radiotherapy for medically operable patients with stage I non-small cell lung cancer.PMID:37563012 | DOI:10.1016/j.canrad.2023.07.012 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - August 10, 2023 Category: Cancer & Oncology Authors: É Martin C Nicolet P Boisselier J Khalifa S Thureau Source Type: research
Role of radiotherapy in the management of rare solid thoracic tumors of the adults
Cancer Radiother. 2023 Aug 7:S1278-3218(23)00140-3. doi: 10.1016/j.canrad.2023.06.025. Online ahead of print.ABSTRACTThoracic tumors include more than one hundred histopathological subtypes. Rare thoracic malignancies can be defined as representing less than 1% of all thoracic tumors. The European Rare Cancer Surveillance Project (RARECARE) identified rarity as an incidence less than 6 for 100,000 people, with significant difference of prevalence between them. Modalities of treatment for these pathologies include surgery, radiotherapy, and systemic therapies. In this article, we aim to discuss role and techniques of radiot...
Source: Cancer Radiotherapie - August 9, 2023 Category: Cancer & Oncology Authors: C Buchalet C Durdux Source Type: research
Targeted systemic treatments and locoregional radiotherapy for breast cancer: Can we expect a benefit from the potentiation of local treatment?
Cancer Radiother. 2023 Aug 7:S1278-3218(23)00153-1. doi: 10.1016/j.canrad.2023.07.011. Online ahead of print.ABSTRACTBreast cancer is the first most common cancer worldwide, and radiation therapy has a major role to play in locoregional adjuvant treatment. In recent years, we have seen the emergence of adjuvant targeted systemic therapies improving the prognosis of patients at high risk of recurrence. Practices concerning combinations of targeted therapies and locoregional radiation therapy for non-metastatic breast cancers often remain heterogeneous due to the low level of evidence and lack of validated recommendations. T...
Source: Cancer Radiotherapie - August 9, 2023 Category: Cancer & Oncology Authors: A Camps Mal éa C Hennequin S Rivera Source Type: research
Surface-guided radiotherapy overview: Technical aspects and clinical applications
Cancer Radiother. 2023 Aug 7:S1278-3218(23)00145-2. doi: 10.1016/j.canrad.2023.07.003. Online ahead of print.ABSTRACTIn radiotherapy, patient positioning has long been ensured by ionizing imaging (kV or MV). Over the past ten years, surface-guided radiotherapy has appeared in radiotherapy departments. It is a continuous three-dimensional acquisition of the surface of the patient, based on the use of several optical cameras. The acquired surface is compared to an expected surface (usually taken from the planning scanner). Operators can constantly appreciate poor position, anatomical deformity or patient shift. Thus, the sys...
Source: Cancer Radiotherapie - August 9, 2023 Category: Cancer & Oncology Authors: J Darr éon C Massabeau C Geffroy P Maroun L Simon Source Type: research
Insights on the carbon footprint of radiotherapy in France
Cancer Radiother. 2023 Aug 7:S1278-3218(23)00151-8. doi: 10.1016/j.canrad.2023.07.009. Online ahead of print.ABSTRACTThe French healthcare system is responsible for 8% of the national footprint. Achieving a net zero emissions scenario will require a 4-5 fold decrease of carbon emissions in the coming years. The carbon footprint of radiation therapy has not been specifically studied to date. In this review we summarize the content of the carbon footprint dedicated session at the annual meeting of the French society of radiation oncology (SFRO). We discuss the French healthcare system carbon footprint and its major drivers a...
Source: Cancer Radiotherapie - August 9, 2023 Category: Cancer & Oncology Authors: M Piffoux G Delpon C Ducrot A Alexis B Allignet C Dupraz M Egnell M Kernec C Milewski S Rivera J Vitr é D Ali S Supiot Source Type: research
Limited applicability and implementation of the international oncology treatments guidelines in low- and middle-income countries, an example from the Mediterranean area borders
Cancer Radiother. 2023 Aug 5:S1278-3218(23)00147-6. doi: 10.1016/j.canrad.2023.07.006. Online ahead of print.ABSTRACTThe quality of cancer care in the modern era is based on a precise diagnosis and personalized therapy according to patients and their disease based on validated guidelines with a high level of evidence. During cancer patients' management, the objective is first to make an accurate diagnosis and then offer the best treatment, validated beforehand in a multidisciplinary board meeting, with the best benefit/risk ratio. In the context of many low- and middle-income countries, the limited available means do not a...
Source: Cancer Radiotherapie - August 7, 2023 Category: Cancer & Oncology Authors: Y Belkacemi M-C Biston N Benchekroun A Benider C Chargari K Debbi M Dor é H El Kacimi I Flandin I Lalya H Samlali N Sellal S Supiot Source Type: research
